Intervention: Minocycline
Trial phase: Phase 1 | Phase 2
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Minocycline 800 mg. loading followed by 200 mg. Q 12 hours.

Minocycline: Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
Eligibility criteria:
Inclusion Criteria:

Male , 18 to 75 years of age, irrespective of race;
Ability to provide written informed consent or have legal representative provide written informed consent;

Must be enrolled in the study within 6 of injury and meet the following criteria:

GCS score of 12 or less within the first 4 hours of injury;
Evidence of neurological injury on computer tomography (CT) of the head;
No known allergy to minocycline or other contraindication to receiving this medication.
Presence of central venous catheter;
Participants must not have a known life-threatening disease prior to the brain injury: However, individuals with a stable medical illness in the opinion of the investigator may be allowed to enter the study;
Participants are not to be on any other interventional studies aimed at enhancing neurorecovery;
Participants are not to be receiving immunosuppressant agents prior to study enrollment.

Exclusion Criteria:

Participant is a female;
Participants, guardians or legal representatives who are unwilling to cooperate with the investigation;
Participants who have received any other investigational drug within 30 days of injury;
Participants known to have severe ischemic heart disease or congestive heart failure, myocardial infarction, spinal cord injury with ongoing deficits, cancer or any other severe illnesses that in the opinion of the investigator would affect the assessment of therapy;
Participants with an ongoing neurological disease/condition or previous stroke or TBI;
Known clinical sequelae of spinal cord injury;
Massive cerebral hemisphere or brainstem hematoma, incompatible with survival;
History of major depression requiring the use of the medication at the time of injury;
Multiple trauma which in the opinion of the investigator, would jeopardize the assessment of therapy;
Participants who have any type of penetrating head injury;
Participants receiving chronic steroid treatment;
Participants receiving isotretinoin;
Lack of informed consent signed by either the participant or the subject's legal representative;
Prior TBI, brain tumor, cerebral vascular event, or other stable brain insult;
Prior history of Pseudotumor cerebri ;
Patients with known renal failure, BUN/ Creatinine 20:1; creatinine > 2 mg/dl;
Patients with known hepatic failure, AST/ALT> 3 x Upper Limit of Normal;
Thrombocytopenia < 75,000/mm;
Known allergy or sensitivity to any of the tetracyclines or any of the components of the product formulation.